NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis

Prestige Consumer Healthcare Inc. (PBH) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

PBH

$47.92

−$1.44 (−2.92%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBH with… →

PBH Key Statistics

As of Oct 21, 2026
Trading
Open
$48.77
Previous Close
$49.36
Day's Range
47.50–48.84
52-Week Range
42.62–71.07
Volume
424.28K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.34
Valuation
Market Cap
$2.27B
P/E Ratio
13.42
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.43
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.56
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.05
EPS (ttm)Profit attributable to each share over the last twelve months.
3.57
Financials (FY)
Revenue (FY)
$1.09B−4.31%
Net Income (FY)
$190.30M−11.32%
Profit marginThe share of revenue left as profit after all costs and taxes.
15.57%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.37M
1-Year Return
−23.32%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
552.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PBH closed at $47.92, −23.32% over 1 year.

Prestige Consumer Healthcare Inc. (PBH) has a market capitalization of $2.27B.

In fiscal 2025, PBH reported revenue of $1.09B.

PBH Stock Return by Calendar Year

Prestige Consumer Healthcare Inc. (PBH) 10-year return: what $10,000 became

1 year
$10,000 $7,668
−23.32%
5 years
$10,000 $8,077
−19.23%
10 years
$10,000 $10,071
+0.71%

If you had invested $10,000 in Prestige Consumer Healthcare Inc. (PBH) 10 years ago, at the close on October 21, 2016, it would have been worth $10,071 at the close on October 21, 2026: +0.71% in total, +0.07% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−22.32%
2025−21.00%
2024+27.56%
2023−2.20%
2022+3.22%
2021+73.93%
2020−13.90%
2019+31.15%
2018−30.47%
2017−14.76%
2016 (partial year)+3.95%

As of October 21, 2026.

PBH Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$1.09B$190.30M17.5%
2024$1.14B$214.61M18.9%
2023$1.13B$209.34M18.6%
2022$1.13B−$82.31M−7.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.09B$595.58M$309.41M$190.30M17.5%
2024$1.14B$634.46M$349.24M$214.61M18.9%
2023$1.13B$624.45M$342.43M$209.34M18.6%
2022$1.13B$625.29M$347.80M−$82.31M−7.3%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

PBH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricPBHDrug Manufacturers - Specialty & Generic medianvs median
P/E13.4220.3134% below
P/S ratio2.052.102% below
Profit margin15.57%−8.14%23.7 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Prestige Consumer Healthcare Inc. (PBH) at $2.27B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 890 employees.

The most recent close on file for PBH is $47.92, dated October 21, 2026. That is −$1.44 (−2.92%) against the previous close. Over the past 52 weeks the price has ranged from $42.62 to $71.07. The latest close sits 12.44% above that 52-week low.

Financial Health

In fiscal 2025, Prestige Consumer Healthcare Inc. reported revenue of $1.09B. That is −4.31% against the prior fiscal year, when revenue was $1.14B. Net income for the same year was $190.30M. That is −11.32% against the prior fiscal year. The reported profit margin is 15.57%. That is 23.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are 3.57.

Across the 4 fiscal years on file, revenue moves from $1.13B in 2022 to $1.09B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 13.42 times earnings. That is 33.94% below the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 9.43. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.56. Measured against sales, the shares trade at 2.05 times revenue. On price-to-sales that is 2.16% below the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.34. Annualized volatility over the trailing 10 years is 29.86%. The trailing one-year total return is −23.32%. Measured over 10 years, that is +0.07% a year compounded.

Growth & Income

No dividend is on file for PBH.

2026 is still running; the total return is −22.32% year to date. The strongest complete calendar year on file is 2021 at +73.93%; the weakest is 2018 at −30.47%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Prestige Consumer Healthcare Inc. (PBH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Prestige Consumer Healthcare Inc. PBH $2.27B 13.4
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Prestige Consumer Healthcare Inc. trades at a P/E of 13.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Visit website →